vs

Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and NATIONAL PRESTO INDUSTRIES INC (NPK). Click either name above to swap in a different company.

ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $164.0M, roughly 1.7× NATIONAL PRESTO INDUSTRIES INC). On growth, NATIONAL PRESTO INDUSTRIES INC posted the faster year-over-year revenue change (21.7% vs 9.4%). Over the past eight quarters, NATIONAL PRESTO INDUSTRIES INC's revenue compounded faster (46.3% CAGR vs 17.5%).

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.

National Presto Industries is a company founded in 1905 in Eau Claire, Wisconsin. Originally called "Northwestern Steel and Iron Works" the company changed its name to the "National Pressure Cooker Company" in 1929 and then National Presto Industries, Inc. 1953. The company originally produced pressure canners for commercial, and later home, use. Beginning in 1939, the company introduced small home-use cooking appliances. The company was admitted to the New York Stock Exchange on March 3, 1969.

ACAD vs NPK — Head-to-Head

Bigger by revenue
ACAD
ACAD
1.7× larger
ACAD
$284.0M
$164.0M
NPK
Growing faster (revenue YoY)
NPK
NPK
+12.3% gap
NPK
21.7%
9.4%
ACAD
Faster 2-yr revenue CAGR
NPK
NPK
Annualised
NPK
46.3%
17.5%
ACAD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACAD
ACAD
NPK
NPK
Revenue
$284.0M
$164.0M
Net Profit
$273.6M
Gross Margin
90.8%
16.9%
Operating Margin
6.1%
11.4%
Net Margin
96.3%
Revenue YoY
9.4%
21.7%
Net Profit YoY
90.3%
EPS (diluted)
$1.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACAD
ACAD
NPK
NPK
Q4 25
$284.0M
$164.0M
Q3 25
$278.6M
$115.5M
Q2 25
$264.6M
$120.4M
Q1 25
$244.3M
$103.6M
Q4 24
$259.6M
$134.7M
Q3 24
$250.4M
$91.8M
Q2 24
$242.0M
$85.1M
Q1 24
$205.8M
$76.7M
Net Profit
ACAD
ACAD
NPK
NPK
Q4 25
$273.6M
Q3 25
$71.8M
$5.3M
Q2 25
$26.7M
$5.2M
Q1 25
$19.0M
$7.6M
Q4 24
$143.7M
Q3 24
$32.8M
$8.1M
Q2 24
$33.4M
$6.1M
Q1 24
$16.6M
$6.6M
Gross Margin
ACAD
ACAD
NPK
NPK
Q4 25
90.8%
16.9%
Q3 25
92.2%
13.9%
Q2 25
92.2%
15.4%
Q1 25
91.7%
17.5%
Q4 24
91.6%
24.3%
Q3 24
92.5%
18.8%
Q2 24
92.5%
17.3%
Q1 24
88.8%
18.1%
Operating Margin
ACAD
ACAD
NPK
NPK
Q4 25
6.1%
11.4%
Q3 25
12.8%
5.6%
Q2 25
12.2%
5.1%
Q1 25
7.9%
8.8%
Q4 24
59.1%
17.3%
Q3 24
12.6%
10.0%
Q2 24
12.6%
7.5%
Q1 24
7.4%
8.2%
Net Margin
ACAD
ACAD
NPK
NPK
Q4 25
96.3%
Q3 25
25.8%
4.6%
Q2 25
10.1%
4.3%
Q1 25
7.8%
7.3%
Q4 24
55.4%
Q3 24
13.1%
8.8%
Q2 24
13.8%
7.1%
Q1 24
8.0%
8.6%
EPS (diluted)
ACAD
ACAD
NPK
NPK
Q4 25
$1.61
Q3 25
$0.42
Q2 25
$0.16
Q1 25
$0.11
Q4 24
$0.86
Q3 24
$0.20
Q2 24
$0.20
Q1 24
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACAD
ACAD
NPK
NPK
Cash + ST InvestmentsLiquidity on hand
$177.7M
$3.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
$395.1M
Total Assets
$1.6B
$500.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACAD
ACAD
NPK
NPK
Q4 25
$177.7M
$3.8M
Q3 25
$258.0M
$4.6M
Q2 25
$253.6M
$4.8M
Q1 25
$217.7M
$5.5M
Q4 24
$319.6M
$22.7M
Q3 24
$155.1M
$33.2M
Q2 24
$177.1M
$53.4M
Q1 24
$204.7M
$87.9M
Stockholders' Equity
ACAD
ACAD
NPK
NPK
Q4 25
$1.2B
$395.1M
Q3 25
$917.3M
$379.8M
Q2 25
$822.4M
$374.1M
Q1 25
$765.2M
$368.6M
Q4 24
$732.8M
$367.6M
Q3 24
$577.2M
$346.6M
Q2 24
$516.7M
$338.1M
Q1 24
$464.0M
$331.6M
Total Assets
ACAD
ACAD
NPK
NPK
Q4 25
$1.6B
$500.7M
Q3 25
$1.3B
$503.8M
Q2 25
$1.2B
$471.9M
Q1 25
$1.1B
$455.3M
Q4 24
$1.2B
$453.4M
Q3 24
$976.9M
$428.9M
Q2 24
$914.1M
$418.1M
Q1 24
$855.1M
$417.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACAD
ACAD
NPK
NPK
Operating Cash FlowLast quarter
$-48.7M
$13.9M
Free Cash FlowOCF − Capex
$12.4M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
-0.18×
TTM Free Cash FlowTrailing 4 quarters
$-36.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACAD
ACAD
NPK
NPK
Q4 25
$-48.7M
$13.9M
Q3 25
$74.3M
$-24.6M
Q2 25
$64.0M
$-10.9M
Q1 25
$20.3M
$12.5M
Q4 24
$40.4M
$-7.6M
Q3 24
$63.2M
$-17.5M
Q2 24
$25.0M
$-33.9M
Q1 24
$29.1M
$5.6M
Free Cash Flow
ACAD
ACAD
NPK
NPK
Q4 25
$12.4M
Q3 25
$73.9M
$-24.7M
Q2 25
$-13.4M
Q1 25
$-10.5M
Q4 24
$-11.3M
Q3 24
$63.2M
$-20.3M
Q2 24
$-34.5M
Q1 24
$5.2M
FCF Margin
ACAD
ACAD
NPK
NPK
Q4 25
7.6%
Q3 25
26.5%
-21.4%
Q2 25
-11.1%
Q1 25
-10.2%
Q4 24
-8.4%
Q3 24
25.2%
-22.1%
Q2 24
-40.6%
Q1 24
6.7%
Capex Intensity
ACAD
ACAD
NPK
NPK
Q4 25
0.9%
Q3 25
0.1%
0.1%
Q2 25
2.0%
Q1 25
22.2%
Q4 24
2.7%
Q3 24
0.0%
3.1%
Q2 24
0.8%
Q1 24
0.5%
Cash Conversion
ACAD
ACAD
NPK
NPK
Q4 25
-0.18×
Q3 25
1.03×
-4.63×
Q2 25
2.40×
-2.12×
Q1 25
1.07×
1.64×
Q4 24
0.28×
Q3 24
1.93×
-2.16×
Q2 24
0.75×
-5.58×
Q1 24
1.76×
0.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACAD
ACAD

Nuplazid$174.4M61%
Daybue$109.6M39%

NPK
NPK

Segment breakdown not available.

Related Comparisons